drugset / Trial / NCT00251368
Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia
Phase 1
Completed
52 enrolled
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabMassachusetts General Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the side effects of 9-Aminocamptothecin (9-AC) and to determine the best dose which should be used to treat leukemia.
Timeline
- Start
- 1995-01
- Primary completion
- 2007-09
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 9-aminocamptothecin | Small molecule | — | Intravenous |